Emadoldin Feyzi

Department of Hematology, St. Olavs University Hospital, Trondheim, Norway, Norway

Poster(s):

• 1416 - CLL18 / MOIRAI: an international phase-III trial aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes in first-line treatment of CLL/SLL